Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
Hansa Biopharma (Nasdaq Stockholm: HNSA) has appointed Maria Törnsén as Chief Operating Officer (COO) and President U.S., effective May 19, 2025. Törnsén brings over 20 years of experience in global and US operations, most recently serving as President North America at Calliditas Therapeutics until its acquisition by Asahi Kasei Corporation in 2024. Her extensive background includes senior leadership roles at Sarepta Therapeutics, Sanofi Genzyme, and Shire plc, where she successfully launched multiple products and led a $1.6Bn global franchise. Törnsén will report to CEO Renée Aguiar-Lucander and join the Executive Committee, bringing her expertise in rare diseases and gene therapy to support IDEFIRIX growth and prepare for upcoming catalysts in H2 2025.
Hansa Biopharma (Nasdaq Stoccolma: HNSA) ha nominato Maria Törnsén come Chief Operating Officer (COO) e Presidente per gli Stati Uniti, con decorrenza dal 19 maggio 2025. Törnsén vanta oltre 20 anni di esperienza nelle operazioni globali e statunitensi, avendo recentemente ricoperto il ruolo di Presidente Nord America presso Calliditas Therapeutics fino all'acquisizione da parte di Asahi Kasei Corporation nel 2024. Il suo vasto background include posizioni di leadership senior presso Sarepta Therapeutics, Sanofi Genzyme e Shire plc, dove ha lanciato con successo numerosi prodotti e guidato un portafoglio globale da 1,6 miliardi di dollari. Törnsén riporterà al CEO Renée Aguiar-Lucander e entrerà a far parte del Comitato Esecutivo, portando la sua esperienza nelle malattie rare e nella terapia genica per sostenere la crescita di IDEFIRIX e prepararsi ai prossimi eventi chiave nella seconda metà del 2025.
Hansa Biopharma (Nasdaq Estocolmo: HNSA) ha nombrado a Maria Törnsén como Directora de Operaciones (COO) y Presidenta para EE. UU., con efecto a partir del 19 de mayo de 2025. Törnsén aporta más de 20 años de experiencia en operaciones globales y estadounidenses, habiendo sido recientemente Presidenta de Norteamérica en Calliditas Therapeutics hasta su adquisición por Asahi Kasei Corporation en 2024. Su amplia trayectoria incluye cargos de liderazgo senior en Sarepta Therapeutics, Sanofi Genzyme y Shire plc, donde lanzó con éxito múltiples productos y lideró una franquicia global de 1.600 millones de dólares. Törnsén reportará a la CEO Renée Aguiar-Lucander y se unirá al Comité Ejecutivo, aportando su experiencia en enfermedades raras y terapia génica para apoyar el crecimiento de IDEFIRIX y prepararse para los próximos hitos en la segunda mitad de 2025.
한사 바이오파마(나스닥 스톡홀름: HNSA)는 2025년 5월 19일부로 마리아 턴센을 최고운영책임자(COO) 겸 미국 지사장으로 임명했습니다. 턴센은 20년 이상의 글로벌 및 미국 내 운영 경험을 보유하고 있으며, 최근까지 2024년 아사히 카세이 코퍼레이션에 인수되기 전까지 칼리디타스 테라퓨틱스에서 북미 사장으로 재직했습니다. 그녀는 사렙타 테라퓨틱스, 사노피 제네자임, 샤이어 plc 등에서 고위 리더십 역할을 수행하며 여러 제품을 성공적으로 출시하고 16억 달러 규모의 글로벌 사업을 이끌었습니다. 턴센은 CEO 르네 아귀아르-루칸더에게 보고하며 경영위원회에 합류해 희귀질환 및 유전자 치료 분야의 전문성을 바탕으로 IDEFIRIX의 성장을 지원하고 2025년 하반기 예정된 주요 이정표를 준비할 예정입니다.
Hansa Biopharma (Nasdaq Stockholm : HNSA) a nommé Maria Törnsén au poste de Chief Operating Officer (COO) et Présidente des États-Unis, à compter du 19 mai 2025. Törnsén apporte plus de 20 ans d’expérience dans les opérations globales et américaines, ayant récemment occupé le poste de Présidente Amérique du Nord chez Calliditas Therapeutics jusqu’à son acquisition par Asahi Kasei Corporation en 2024. Son parcours étendu inclut des postes de direction chez Sarepta Therapeutics, Sanofi Genzyme et Shire plc, où elle a lancé avec succès plusieurs produits et dirigé une franchise mondiale de 1,6 milliard de dollars. Törnsén reportera à la CEO Renée Aguiar-Lucander et rejoindra le Comité Exécutif, apportant son expertise en maladies rares et thérapie génique pour soutenir la croissance d’IDEFIRIX et préparer les prochains catalyseurs du second semestre 2025.
Hansa Biopharma (Nasdaq Stockholm: HNSA) hat Maria Törnsén mit Wirkung zum 19. Mai 2025 zur Chief Operating Officer (COO) und Präsidentin für die USA ernannt. Törnsén bringt über 20 Jahre Erfahrung in globalen und US-amerikanischen Geschäftsabläufen mit und war zuletzt Präsidentin Nordamerika bei Calliditas Therapeutics bis zur Übernahme durch die Asahi Kasei Corporation im Jahr 2024. Ihr umfangreicher Hintergrund umfasst leitende Führungspositionen bei Sarepta Therapeutics, Sanofi Genzyme und Shire plc, wo sie erfolgreich mehrere Produkte auf den Markt brachte und ein globales Franchise im Wert von 1,6 Milliarden US-Dollar leitete. Törnsén wird an CEO Renée Aguiar-Lucander berichten und dem Executive Committee beitreten, um mit ihrer Expertise in seltenen Krankheiten und Gentherapie das Wachstum von IDEFIRIX zu unterstützen und sich auf die kommenden Meilensteine in der zweiten Hälfte 2025 vorzubereiten.
- Appointment of experienced executive with over 20 years in global and US operations
- Strong track record in rare diseases and gene therapy sectors
- Proven success in launching products and managing $1.6Bn global franchise
- Strategic timing ahead of multiple anticipated catalysts in H2 2025
- None.
Maria Törnsén has more than 20 years experience across global and US operations, where she held multiple senior commercial leadership roles. Most recently, she held the position of President North America at Calliditas Therapeutics, where she was responsible for the US commercial and medical affairs organization, until it was acquired by Asahi Kasei Corporation of
"We are pleased to welcome Ms Törnsén to the executive management team as COO and President of the US business. She brings invaluable experience in the area of rare diseases and gene therapy, from building commercial organizations, launching new products and driving growth and profitability, which will be critical as we prepare for the next phase of our development," said CEO Renée Aguiar-Lucander.
"I am delighted to join Hansa at this exciting time in the company's history. I look forward to working with the Hansa team and leveraging my experience from prior roles, to support the continued growth of IDEFIRIX and prepare for multiple anticipated catalysts in the second half of 2025," said Maria Törnsén.
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB,
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
250513-HNSA COO US president_ENG |
View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-appoints-maria-tornsen-as-chief-operating-officer-and-president-us-302453449.html
SOURCE Hansa Biopharma AB
FAQ
Who is Maria Törnsén and what is her new role at Hansa Biopharma (HNSA)?
What is Maria Törnsén's professional background before joining Hansa Biopharma (HNSA)?
What are the immediate priorities for Maria Törnsén at Hansa Biopharma (HNSA)?
When does Maria Törnsén start her role as COO at Hansa Biopharma (HNSA)?
